Neurogene Inc.
NGNE
$19.98
-$0.01-0.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 23.01% | 32.04% | 25.96% | 40.32% | 52.54% |
| Gross Profit | -30.68% | -32.04% | -25.96% | -40.32% | -43.58% |
| SG&A Expenses | 26.34% | 55.77% | 141.86% | 63.16% | 133.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.85% | 38.69% | 46.01% | 45.74% | 67.19% |
| Operating Income | -29.54% | -38.69% | -46.01% | -45.74% | -59.84% |
| Income Before Tax | -19.06% | -33.84% | -918.88% | -38.69% | -55.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.06% | -33.84% | -918.88% | -38.69% | -55.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.06% | -33.84% | -918.88% | -38.69% | -55.92% |
| EBIT | -29.54% | -38.69% | -46.01% | -45.74% | -59.84% |
| EBITDA | -31.05% | -40.83% | -48.97% | -48.52% | -64.08% |
| EPS Basic | 4.21% | -7.75% | -101.23% | 96.35% | 95.91% |
| Normalized Basic EPS | 4.21% | -8.32% | 95.39% | 96.35% | 95.91% |
| EPS Diluted | 4.21% | -7.75% | -133.21% | 96.35% | 95.91% |
| Normalized Diluted EPS | 4.21% | -8.32% | -24.11% | 96.35% | 95.91% |
| Average Basic Shares Outstanding | 24.28% | 24.21% | 2,927.90% | 3,698.66% | 3,711.36% |
| Average Diluted Shares Outstanding | 24.28% | 24.21% | 12.52% | 3,698.66% | 3,711.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |